Progressive Fibrosing Interstitial Lung Disease (pfild) - Epidemiology Forecast - 2032

This ‘Progressive Fibrosing Interstitial Lung Disease (PF-ILD)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the PF-ILD trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Progressive Fibrosing Interstitial Lung Disease Understanding

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.

Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.

Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation majorly includes, Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs.

Progressive Fibrosing Interstitial Lung Disease Diagnosis

Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), is key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.

The differential diagnosis of Interstitial Lung Diseases requires a multidisciplinary approach, usually involving pulmonologist, radiologist, and pathologist. The evaluations include clinical presentation, specific history assessment, smoking status, lung function evaluation, serological test results, imaging and if required, lung biopsy.

Progressive Fibrosing Interstitial Lung Disease Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Progressive Fibrosing Interstitial Lung Disease (PF-ILD), in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2019 to 2032.

Progressive Fibrosing Interstitial Lung Disease Detailed Epidemiology Segmentation

• In the assessment done by the publisher, the estimated total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) in the 7MM were 322,197 in 2021.
• The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of PF-ILD with 31,807 cases, followed by the United Kingdom, which had prevalent population of 25,446 in 2021. On the other hand, Spain had the lowest prevalent population (17,834 cases).
• Japan had 31,542 total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease in 2021, accounting for approximately 10% in 7MM.

Scope of the Report

• The report covers the descriptive overview of Progressive Fibrosing Interstitial Lung Disease, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• The report assesses the disease risk and burden of Progressive Fibrosing Interstitial Lung Disease.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Report Highlights

• 11-Year Forecast of Progressive Fibrosing Interstitial Lung Disease
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Progressive Fibrosing Interstitial Lung Disease

Key Questions Answered

• What are the disease risk and burden of Progressive Fibrosing Interstitial Lung Disease?
• What is the historical Progressive Fibrosing Interstitial Lung Disease patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Progressive Fibrosing Interstitial Lung Disease at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Progressive Fibrosing Interstitial Lung Disease?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Progressive Fibrosing Interstitial Lung Disease during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Progressive Fibrosing Interstitial Lung Disease report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM+ Progressive Fibrosing Interstitial Lung Disease epidemiology forecast.
• The Progressive Fibrosing Interstitial Lung Disease epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Progressive Fibrosing Interstitial Lung Disease epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032